Experimental combo therapy for advanced breast cancer tested in small early trial
NCT ID NCT06878248
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 28 times
Summary
This early-phase study tested a new treatment for people with advanced breast cancer that had stopped responding to standard therapies. The treatment combined a patient's own engineered immune cells (CLBR001) with an antibody drug (ABBV-461). The study aimed to find the safest dose and check for side effects, but it was terminated early after enrolling only 10 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.